Ms. Haseena P A is a PhD student at centre for brain research, Indian Institute of Science, Bangalore. She is working on the project titled as “study of actin modulators at the synapse and their role in Alzheimer’s disease”. She is trying to investigate the synaptosomal actin interactome in wildtype and APP/PS1 mice and found out the critical role of PSD-95 association at the synapse with actin, AMPA and NMDA receptors. Prior to joining for PhD, She has worked as a junior research fellow at Amrita Centre for Nanosciences and Molecular Medicine, Kochi, where she was interested in studying low cost nanocomposite scaffolds for tissue regeneration. She has also worked as a project assistant at Indian Institute of Science, Bangalore in a project titled “the role nervous system regulation of innate immune responses in C. elegans. She has completed her master’s in Biotechnology and has a good academic record. She has also qualified the prestigious CSIR-Shyama Prasad Mukherjee fellowship and Graduate Aptitude Test in Engineering (GATE) Biotechnology.

After completing my MD from Ziauddin University, Pakistan, I joined the Pascoal Lab at the University of Pittsburgh as a postdoctoral fellow. My journey as a clinician scientist has been exciting under Tharick Pascoal's brilliant mentorship. As a clinician scientist, I'm interested in studying the sex differences seen in Alzheimer's disease and its implications in the field of AD research and eventually, clinical practice.

Carla Abdelnour Ruiz, MD, Ph.D. is a neurologist, and Sue Berghoff LBD postdoctoral researcher at Stanford University investigating Lewy body disease. Her plan is to study the impact of Alzheimer´s disease co-pathology in the clinical presentation, cognitive profile, and disease progression of Lewy body disease. Additionally, she wants to study the biological underpinnings of prodromal Lewy body disease to identify potential biomarkers for diagnosis and prognosis. She is a board member of the Lewy Body Dementia Association (LBDA), and was a member of the steering committee of the European dementia with Lewy bodies consortium (E-DLB).

Dr. Abisambra is Associate Professor of Neuroscience in the CTRND, Vice-Chair of Strategic Operations in the Department of Neuroscience, Deputy Director of the BRAIN Injury Center, and Assistant Dean of Diversity & Health Equity at the University of Florida College of Medicine. The overarching goal of his research program is to investigate the molecular mechanisms linking tau and RNA translation with neurodegeneration. This focus creates the opportunity to investigate the integration of essential cellular functions for development, aging, and disease by targeting one protein. Tauopathies such as Alzheimer's disease, fronto-temporal dementia, and chronic traumatic encephalopathy are central to his research. Ultimately, this work can aid in the identification of biomarkers and therapeutic targets for more than 30 million people currently suffering from tauopathies worldwide.

I am Adebisi Benjamin Tèmídayọ, a Researcher and Academic with Osun State University, Nigeria. I am also a Social Crusader, Author, Educator, Entertainer and Critical Thinker. I study and teach the Human Brain and the pathological conditions, associated with it. My Areas of Specialities include Neurology, Psychiatry and Neurodegenerative Diseases, specifically, Parkinson's Diseases. I had my Fellowship Training at University Medical Center, Groningen, The Netherlands. I have published my works with Elsevier, Cambridge University Press and Wiley's Online Library. I am also a Member of several International Organisations and I have made presentations and moderated International conferences across the Globe. I am a Lover of God and His Word and also a Researcher of the Truth.

Emmanuel has broad and well-developed skills in several aspects of biomedical and health sciences. For many years, he practiced as a public health-oriented hospital pharmacist. Emmanuel holds a PhD in statistical genetics and genomic epidemiology. He is currently a postdoctoral research fellow in the Centre for Precision Health, Edith Cowan University where he researches the roles of genetics in the risk of Alzheimer’s disease and comorbidities.

Dr. Afroz’s research has focused on understanding molecular mechanisms of neurodegeneration and pathways for therapeutic interventions in various CNS indications. At AC Immune, Dr. Afroz serves as Team and project leader for TDP-43 therapeutic antibody program. Prior to joining AC Immune in 2017, Dr. Afroz was a post-doctoral scientist at the University of Zürich where he investigated the pathways that trigger aggregation of ALS/FTD-linked proteins, the mechanisms of neurotoxicity and the molecular basis of disease heterogeneity. Dr. Afroz obtained his master’s degree in Biotechnology at the Indian Institute of Technology in Mumbai. In 2013, he obtained his Ph.D. in Molecular Biology and Biophysics at ETH Zürich where he studied the role of sequence-specific protein-RNA interactions in RNA processing and metabolism.

I am the Vice President, Professor, and Head of the Department of Molecular Immunology at the Institute for Molecular Medicine (IMM) in Huntington Beach, California. Before coming to IMM, I was Visiting Professor at the University of Pennsylvania (UPENN). After moving in the year 2000 from UPENN to IMM, I have focused my vast experience in vaccine development on the generation and testing of the novel MultiTEP vaccine platform technology for neurodegenerative disorders. More specifically, to overcome serious concerns regarding the limited ability of the elderly to mount an effective immune response to active immunizations, I proposed taking advantage of pre-existing memory CD4+T helper (Th) cells that were generated in response to conventional public health vaccination programs and/or infections with various pathogens. Using this technology, we developed recombinant and nucleic acid-based preventive vaccines targeting pathological amyloid (AV-1959) and tau (AV-1980) separately or together (DUVAX) for Alzheimer’s and different tauopathies. One of these vaccines, AV-1959D is currently in the clinical trial (IND18953), and another, AV-1980R, will be ready for Phase 1 soon. Recently, we completed efficacy studies with MultiTEP platform-based Dementia Lewy Body and Parkinson’s disease preventive vaccine targeting 3 pathological α-synuclein regions simultaneously. Multiple papers have been published on MultiTEP-based vaccines against AD/PD.

Dr Aguayo has an MD from the Catholic University of Chile, an MSc in clinical epidemiology from the Erasmus University Rotterdam and a PhD in public health from the University of Liège. She currently works in the deep digital phenotyping research unit at the Department of Precision Health at the Luxembourg Institute of Health. She also participates in the National Centre for Excellence in Research on Parkinson's Disease (NCER-PD) as an epidemiologist. Her main interests are the epidemiology of Parkinson's and its risk factors, healthy ageing, frailty trajectories, diabetes, digital health and sleep patterns. She is interested in methodology techniques such as multiple imputations, longitudinal trajectory analysis, survival analysis, clustering and deep learning. She has participated in designing clinical trials and observational studies in the general population, adding objective measures of sleep and physical functioning and studying the impact of quantity and quality of sleep on disease and disease risk.

Karen studied Psychology at Las Villas University, Santa Clara, Cuba and graduated as Bachelor of Psychology in 2009. Then, she joined the research Group of Cognitive and Social Neurosciences at Cuban Center for Neuroscience (CNEURO) Cuba. She received her first MS degree in 2014 at Villa Clara University of Medical Sciences and her second MS degree in 2016 at CNEURO. She was awarded a scholarship by the Fonds de Recherche du Québec (FRQS) supervised by Professor Natalie Phillips, Ph.D. at the Department of Psychology, Concordia University, Canada. Also, she has interacted with researchers at the Montreal Neurological Institute (MNI). In 2016, she obtained the position of Head of the project “Technologies for the management of brain aging” at the Department of Cognitive and Social Neurosciences, CNEURO.

A physiotherapist who finished her Master studies in the international program "Physical Activity and Health" from Friedrich-Alexander University-Germany. Currently, working as a research associate and PhD student in the Active-ageing working group, Institute of Sports Science-Münster University-Germany, focusing on digital health promotion, and identifying the needs of all parties involved in the healthcare of the neurodegenerative diseases in developing digital healthcare solutions.